文献速递乳腺癌

BEECH试验中早期ctDNA动态作为晚期乳腺癌无进展生存期的替代指标

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
PubMed 文献 · Ann Oncol · 2019-01-01

BEECH I/II期随机试验在雌激素受体阳性晚期转移性乳腺癌患者中,比较紫杉醇联合安慰剂与紫杉醇联合AKT抑制剂capivasertib,利用基线及治疗中血浆样本分析ctDNA动态。开发队列显示治疗8天后ctDNA抑制明显(P=0.014),第2周期第1天(4周)为预测PFS的最佳时间点;验证队列中4周时ctDNA抑制者中位PFS为11.1个月,高ctDNA者为6.4个月(HR=0.20,95%CI 0.083-0.50,P<0.0001)。

要点

  • 治疗4周时ctDNA抑制可独立预测PFS,验证队列HR=0.20(95%CI 0.083-0.50,P<0.0001)。
  • capivasertib组与安慰剂组总体ctDNA抑制水平无差异(P=0.904),PIK3CA突变亚组亦无差异(P=0.071)。
  • 基线样本中30%(18/59)存在意义未明的克隆性造血(CHIP),CHIP对化疗耐受性和PFS均无影响。

核心结论

  • 早期治疗中ctDNA动态是无进展生存期的替代指标,动态ctDNA评估有潜力显著增强早期药物开发。

研究设计与样本

  • 利用BEECH I/II期随机试验(紫杉醇联合安慰剂对比紫杉醇联合AKT抑制剂capivasertib)的患者血浆样本进行ctDNA分析。
  • 开发队列(安全性导入期,A部分)和验证队列(随机化部分,B部分)在基线和多个治疗时间点采集血浆样本。
  • 基线样本ctDNA测序识别突变用于纵向分析,采用突变特异性微滴数字PCR(ddPCR)检测评估基线与872份治疗中样本间ctDNA丰度(等位基因分数)变化。

主要发现

  • 开发队列中治疗8天后ctDNA抑制明显(P=0.014),第2周期第1天(4周)被确定为预测PFS的最佳时间点。
  • 验证队列中4周时ctDNA抑制者中位PFS为11.1个月,高ctDNA者为6.4个月(HR=0.20,95%CI 0.083-0.50,P<0.0001)。
  • capivasertib组与安慰剂组总体ctDNA抑制水平无差异(P=0.904),PIK3CA突变亚组亦无差异(P=0.071)。
  • 基线样本中30%(18/59)存在意义未明的克隆性造血(CHIP),CHIP对化疗耐受性和PFS均无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression-free survival (PFS) and early predictor of drug efficacy. PATIENTS AND METHODS: Patients with estrogen receptor-positive advanced metastatic breast cancer (ER+ mBC) in the BEECH study, paclitaxel plus placebo versus paclitaxel plus AKT inhibitor capivasertib, had plasma samples collected for ctDNA analysis at baseline and at multiple time points in the development cohort (safety run-in, part A) and validation cohort (randomised, part B). Baseline sample ctDNA sequencing identified mutations for longitudinal analysis and mutation-specific digital droplet PCR (ddPCR) assays were utilised to assess change in ctDNA abundance (allele fraction) between baseline and 872 on-treatment samples. Primary objective was to assess whether early suppression of ctDNA, based on pre-defined criteria from the development cohort, independently predicted outcome in the validation cohort. RESULTS: In the development cohort, suppression of ctDNA was apparent after 8 days of treatment (P = 0.014), with cycle 2 day 1 (4 weeks) identified as the optimal time point to predict PFS from early ctDNA dynamics. In the validation cohort, median PFS was 11.1 months in patients with suppressed ctDNA at 4 weeks and 6.4 months in patients with high ctDNA (hazard ratio = 0.20, 95% confidence interval 0.083-0.50, P < 0.0001). There was no difference in the level of ctDNA suppression between patients randomised to capivasertib or placebo overall (P = 0.904) nor in the PIK3CA mutant subpopulation (P = 0.071). Clonal haematopoiesis of indeterminate potential (CHIP) was evident in 30% (18/59) baseline samples, although CHIP had no effect on tolerance of chemotherapy nor on PFS. CONCLUSION: Early on-treatment ctDNA dynamics are a surrogate for PFS. Dynamic ctDNA assessment has the potential to substantially enhance early drug development. CLINICAL REGISTRATION NUMBER: NCT01625286.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hrebien S, Citi V, Garcia-Murillas I, et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. 2019. PMID: 30860573. doi:10.1093/annonc/mdz085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。